Transvaginal ultrasound guided trigone and bladder injection: A cadaveric feasibility study for a novel route of intradetrusor chemodenervation

다국어 초록 (Multilingual Abstract)

Purpose: OnabotulinumtoxinA (BTX) detrusor chemodenervation is an efficacious third-line treatment for overactive bladder. Despite high clinical efficacy rates for BTX injection, many patients refuse initial or repeat treatment due to the invasiveness of the cystoscopic route of delivery. We assess the feasibility of injecting the trigone and posterior bladder wall via a transvaginal route under ultrasound guidance using a human cadaveric model.
Materials and Methods: Eight de-identified anonymous fresh female deceased donor cadaver pelvises were placed in supine split leg position. A transvaginal ultrasound probe guided injections of India ink into the trigone in 3 sites and the posterior wall in 2 sites. Full thickness bladder biopsies were then obtained and histologic analysis was performed to confirm presence of India ink in the detrusor layer.
Results: The mean time from day of death was 11.0 days (range, 4.0–23.0 days). Three to five bladder biopsies were obtained per cadaver, for a total of 34 specimens (20 trigone, 14 posterior wall). Histologic analysis revealed presence of India ink within the detrusor layer in 8/8 (100.0%) of cadavers. The surgeon's perception of appropriate targeting under ultrasound guidance was confirmed in 8/8 cadavers (100.0%) involving the bladder trigone, and 7/8 (87.5%) involving the posterior wall. Of injections that were believed to have appropriately targeted the detrusor layer, 22/34 specimens (64.7%) demonstrated the presence of India ink under histologic analysis.
Conclusions: Intradetrusor injection of the bladder trigone and posterior wall under transvaginal ultrasound guidance is feasible and has acceptable accuracy.

참고문헌 (Reference)

1 Choquet O, "Where should the tip of the needle be located in ultrasound‐guided peripheral nerve blocks" 25 : 596-602, 2012

2 Sermus LA, "Ultrasound-guided approach to nerves (direct vs. tangential) and the incidence of intraneural injection: a cadaveric study" 72 : 461-469, 2017

3 Oelke M, "Ultrasound measurement of detrusor wall thickness in healthy adults" 25 : 308-317, 2006

4 Blatt AH, "Ultrasound measurement of bladder wall thickness in the assessment of voiding dysfunction" 179 : 2275-2278, 2008

5 Bartley J, "Transvaginal trigger point injections improve pain scores in women with pelvic floor hypertonicity and pelvic pain conditions" 2018

6 Gupta P, "Transvaginal pelvic floor muscle injection technique : a cadaver study" 23 : 61-63, 2017

7 Sun Y, "The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis" 47 : 1779-1788, 2015

8 Pinto R, "Results from a randomized, double blind, placebo-controlled trial to evaluate efficacy and safety of intra-trigonal injection of onabotulinum toxin A in patients with bladder pain syndrome/ interstitial cystitis" 197 (197): e46-, 2017

9 Spradling K, "Redefining the autonomic nerve distribution of the bladder using 3-dimensional image reconstruction" 194 : 1661-1667, 2015

10 Manecksha RP, "Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity" 61 : 928-935, 2012

11 Nitti VW, "OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence : results of a phase 3, randomized, placebo controlled trial" 189 : 2186-2193, 2013

12 Dobberfuhl AD, "No Adverse change in ambulatory voiding function after trigone onabotulinumtoxinA detrusor injection in the rat"

13 Kuo HC, "Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography" 20 : 1293-1299, 2009

14 Rahnama'i MS, "Long-term compliance and results of intravesical botulinum toxin A injections in male patients" 36 : 1855-1859, 2017

15 Lucioni A, "Intravesical botulinum type A toxin injection in patients with overactive bladder : trigone versus trigone-sparing injection" 13 : 3291-3295, 2006

16 Kuhn A, "How should bladder wall thickness be measured? A comparison of vaginal, perineal and abdominal ultrasound" 29 : 1393-1396, 2010

17 Gormley EA, "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline" 188 (188): 2455-2463, 2012

18 Alsinnawi M, "Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection" 47 : 893-898, 2015

19 Abdel-Meguid TA, "Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial" 184 : 2423-2428, 2010

20 Yang JM, "Bladder wall thickness on ultrasonographic cystourethrography : affecting factors and their implications" 22 : 777-782, 2003

21 Kuo HC, "Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics" 30 : 1242-1248, 2011

22 Dobberfuhl AD, "Ambulatory and cystometric response following single versus multiple onabotulinumtoxina detrusor injections in a rat model of overactive bladder induced by intravesical acetic acid" 147-, 2017

23 Stav K, "Adverse effects of cystoscopy and its impact on patients’ quality of life and sexual performance" 6 : 474-478, 2004

24 Chuan A, "A randomised controlled trial comparing meat‐based with human cadaveric models for teaching ultrasound‐guided regional anaesthesia" 71 : 921-929, 2016

25 Khullar V, "A novel technique for measuring bladder wall thickness in women using transvaginal ultrasound" 4 : 220-223, 1994

26 Mehnert U, "A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging" 27 : 397-403, 2009